JP2012505837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505837A5 JP2012505837A5 JP2011531312A JP2011531312A JP2012505837A5 JP 2012505837 A5 JP2012505837 A5 JP 2012505837A5 JP 2011531312 A JP2011531312 A JP 2011531312A JP 2011531312 A JP2011531312 A JP 2011531312A JP 2012505837 A5 JP2012505837 A5 JP 2012505837A5
- Authority
- JP
- Japan
- Prior art keywords
- annexin
- composition
- effective
- amount
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000672 Annexin A5 Proteins 0.000 claims description 68
- 102000004121 Annexin A5 Human genes 0.000 claims description 62
- 239000000203 mixture Substances 0.000 claims description 28
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 230000000770 proinflammatory effect Effects 0.000 claims description 16
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- 206010040047 Sepsis Diseases 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 230000004768 organ dysfunction Effects 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 6
- 210000002216 heart Anatomy 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 241000700159 Rattus Species 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10639008P | 2008-10-17 | 2008-10-17 | |
| US61/106,390 | 2008-10-17 | ||
| PCT/CA2009/001469 WO2010043045A1 (en) | 2008-10-17 | 2009-10-16 | Annexin and its use to treat inflammatory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505837A JP2012505837A (ja) | 2012-03-08 |
| JP2012505837A5 true JP2012505837A5 (enExample) | 2012-12-06 |
| JP5590621B2 JP5590621B2 (ja) | 2014-09-17 |
Family
ID=42106169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531312A Active JP5590621B2 (ja) | 2008-10-17 | 2009-10-16 | 炎症性障害の処置を処置するためのアネキシンおよびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9192649B2 (enExample) |
| EP (1) | EP2349321B1 (enExample) |
| JP (1) | JP5590621B2 (enExample) |
| CN (1) | CN102256617B (enExample) |
| CA (1) | CA2740557C (enExample) |
| WO (1) | WO2010043045A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5590621B2 (ja) | 2008-10-17 | 2014-09-17 | ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド | 炎症性障害の処置を処置するためのアネキシンおよびその使用 |
| EP2380023A2 (en) | 2008-12-19 | 2011-10-26 | Medirista Biotechnologies AB | Oxidized cardiolipin as a novel pro-inflammatory factor |
| WO2011160845A2 (en) | 2010-06-24 | 2011-12-29 | Medirista Biotechnologies Ab | Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment |
| CN102690345B (zh) * | 2011-03-24 | 2014-03-19 | 江苏靶标生物医药研究所有限公司 | 人膜联蛋白v变体及其表达、制备和应用 |
| PL2720707T3 (pl) * | 2011-06-15 | 2019-06-28 | Resother Pharma Aps | Przeciwzapalne produkty farmaceutyczne |
| WO2013124327A1 (en) | 2012-02-21 | 2013-08-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Tim receptors as virus entry cofactors |
| WO2013124324A1 (en) | 2012-02-21 | 2013-08-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Tam receptors as virus entry cofactors |
| WO2014077575A1 (ko) * | 2012-11-13 | 2014-05-22 | 다인바이오 주식회사 | 덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물 |
| GB2542391A (en) * | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
| GB201702144D0 (en) * | 2017-02-09 | 2017-03-29 | Annexin Pharmaceuticals Ab | Therapeutic compositions |
| WO2019238550A1 (en) * | 2018-06-12 | 2019-12-19 | Universiteit Maastricht | Method for the treatment of hypoxic-ischemic encephalopathy in newborns |
| CN109529017B (zh) * | 2018-12-25 | 2022-06-14 | 江苏靶标生物医药研究所有限公司 | 一种膜联蛋白v的应用 |
| US11357823B2 (en) * | 2019-08-30 | 2022-06-14 | Suzhou Yabao Pharmaceutical R&D Co., Ltd | Method for treating cerebral stroke |
| US20220193192A1 (en) * | 2019-08-30 | 2022-06-23 | Suzhou Yabao Pharmaceutical R&D Co Ltd | Methods of treating a traumatic brain injury |
| CN112057623A (zh) * | 2020-06-03 | 2020-12-11 | 江苏靶标生物医药研究所有限公司 | 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用 |
| US20230374091A1 (en) * | 2020-10-09 | 2023-11-23 | London Health Sciences Centre Research Inc. | Annexin a5 compositions and methods |
| CN112618696B (zh) * | 2020-12-14 | 2023-05-05 | 南京大学 | Annexin A5在制备治疗胆汁淤积药物中的应用 |
| CN115245559A (zh) * | 2021-04-25 | 2022-10-28 | 上海萨美细胞技术有限公司 | 一种用于治疗肺损伤的药物 |
| CN117186239A (zh) * | 2022-01-30 | 2023-12-08 | 南京瑞初医药有限公司 | 融合蛋白及其应用 |
| CN118001375A (zh) * | 2023-04-12 | 2024-05-10 | 上海萨美细胞技术有限公司 | 一种用于难愈性创面修复的药物 |
| CN119097689A (zh) * | 2023-06-08 | 2024-12-10 | 上海萨美细胞技术有限公司 | 一种用于治疗卵巢功能不全的药物 |
| CN118001372A (zh) * | 2023-07-04 | 2024-05-10 | 上海萨美细胞技术有限公司 | 膜联蛋白在抗衰老中的用途 |
| CN119158000B (zh) * | 2023-10-25 | 2025-07-18 | 上海萨美细胞技术有限公司 | 一种用于治疗肺纤维化的药物 |
| WO2025129329A1 (en) * | 2023-12-23 | 2025-06-26 | London Health Sciences Centre Research Inc. | Methods for treatment of sepsis |
| CN118203650B (zh) * | 2024-01-26 | 2025-04-29 | 上海萨丽斐生物科技有限公司 | 一种用于治疗色素沉着的药物 |
| CN118846001B (zh) * | 2024-07-09 | 2025-09-02 | 上海萨丽斐生物科技有限公司 | 一种具有保湿、修护、紧致、抗皱功效的组合物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0339285A3 (en) * | 1988-03-31 | 1989-11-29 | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) | Recombinant endonexin ii |
| US5229367A (en) * | 1991-01-21 | 1993-07-20 | Sclavo S.P.A. | Antiinflammatory peptide derived from human lipocortin V |
| NZ283171A (en) | 1994-04-11 | 1998-02-26 | Nexins Research Bv | Detecting or quantifying apoptotic cells in a sample |
| US7645739B2 (en) * | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
| US20030152513A1 (en) | 2001-09-06 | 2003-08-14 | Imetrix, Inc. | Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector |
| WO2003103577A2 (en) | 2002-06-06 | 2003-12-18 | Tze Chein Wun | Novel recombinant anticoagulant proteins |
| WO2005099744A1 (en) | 2004-04-15 | 2005-10-27 | Athera Biotechnologies Ab | Annexin v for preventing atherothrombois and plaque rupture |
| EP2173342A2 (en) | 2007-06-22 | 2010-04-14 | ETH Zurich | Antivirals |
| MX2010001194A (es) * | 2007-07-31 | 2010-07-30 | Univ Louisiana State | Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones. |
| EP2234631B1 (en) | 2007-12-18 | 2012-09-12 | Athera Biotechnologies AB | Compounds and methods for the treatment of vascular disease |
| TR201909412T4 (tr) | 2008-02-22 | 2019-07-22 | Annexin Pharmaceuticals Ab | Restenozun önlenmesi veya tedavisi için bileşikler ve yöntemler. |
| JP5590621B2 (ja) | 2008-10-17 | 2014-09-17 | ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド | 炎症性障害の処置を処置するためのアネキシンおよびその使用 |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
-
2009
- 2009-10-16 JP JP2011531312A patent/JP5590621B2/ja active Active
- 2009-10-16 EP EP09820159.3A patent/EP2349321B1/en not_active Revoked
- 2009-10-16 CA CA2740557A patent/CA2740557C/en active Active
- 2009-10-16 US US13/124,330 patent/US9192649B2/en active Active
- 2009-10-16 WO PCT/CA2009/001469 patent/WO2010043045A1/en not_active Ceased
- 2009-10-16 CN CN200980150927.0A patent/CN102256617B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505837A5 (enExample) | ||
| Kim et al. | Mechanisms of radiation-induced skin injury and implications for future clinical trials | |
| Tetè et al. | IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation | |
| AR097588A2 (es) | Agentes ligantes inhibidores de la miostatina, molécula de ácido nucleico que la codifica, vector de expresión, célula huésped incapaz de regenerar una planta o un animal, método para prepararlo, composición farmacéutica que lo comprende, su uso para la manufactura de un medicamento y método para medir miostatina en una muestra | |
| JP2006516116A5 (enExample) | ||
| JP2010520304A5 (enExample) | ||
| SG188144A1 (en) | Alpha 7 nicotinic agonists and antipsychotics | |
| RU2012124268A (ru) | Бензимидазольные соединения и их применения | |
| Wen et al. | SDF-1α and CXCR4 as therapeutic targets in cardiovascular disease | |
| JP2017536380A5 (enExample) | ||
| CN110041408A (zh) | 一种小分子多肽及其在制备防治帕金森综合症药物中的应用 | |
| Fakhoury et al. | Use of artificial cell microcapsule containing thalidomide for treating TNBS-induced Crohn's disease in mice | |
| Cheng et al. | Anti-inflammatory effect of stem cells against spinal cord injury via regulating macrophage polarization | |
| JP2018530577A (ja) | 神経変性疾患の治療のための方法および組成物 | |
| US10639296B2 (en) | Methods to mitigate injury from radiation exposure | |
| CN108114284A (zh) | Fxr激动剂与凋亡抑制剂联用在制备优效抗肝纤维化药物中的应用 | |
| JP2009538935A5 (enExample) | ||
| CN102552280A (zh) | 甘草酸或盐及其衍生物的制药用途 | |
| CN104622874B (zh) | Ccr4拮抗剂在抑制癌生长及转移中的应用 | |
| CN105854018A (zh) | Wnt抑制剂在制备治疗造血再生障碍性疾病药物中的应用 | |
| CN105030822B (zh) | 有机无机杂化多阴金属氧酸盐化合物的用途 | |
| JP2020518588A5 (enExample) | ||
| CN116236490A (zh) | 脱氧胆酸的用途及药物 | |
| JP2014512369A5 (enExample) | ||
| JPWO2018151285A1 (ja) | 掻痒性皮膚疾患の予防又は治療薬 |